Loss of normal cyclical $\beta_2$ adrenoceptor regulation and increased premenstrual responsiveness to adenosine monophosphate in stable female asthmatic patients

Kia Soong Tan, Lesley C McFarlane, Brian J Lipworth

Abstract

Background – A study was undertaken to investigate the influence of the menstrual cycle on airway responsiveness and $\beta_2$ adrenoceptor function in female asthmatic patients. It has previously been shown that normal women exhibit cyclical changes in $\beta_2$ adrenoceptor function with an increase in $\beta_2$ adrenoceptor density in the luteal phase during the premenstrual period. Methods – Fifteen women with stable, well controlled asthma (mean forced expiratory volume in one second (FEV1) 2.97 (0.11) l (93.8% predicted)) were evaluated. Measurements were made at the follicular phase (days 1–6) and the luteal phase (days 21–24) of the menstrual cycle. Airway responsiveness was assessed using adenosine 5'-monophosphate (AMP) and expressed as $PC_{20}$ AMP. $Beta_2$ adrenoceptor function was evaluated by measuring lymphocyte $\beta_2$ adrenoceptor parameters and constructing dose-response curves to salbutamol (100–1600 $\mu$g). The levels of female sex hormones were also measured at both phases of the cycle.

Results – There were significant increases in serum levels of both oestradiol (2.2-fold, $p < 0.001$) and progesterone (7.2-fold, $p < 0.05$) between the follicular and luteal phases. Geometric mean $PC_{20}$ AMP was 19.0 mg/ml and 7.6 mg/ml during the follicular and luteal phases, respectively ($p < 0.05$), a 2.51-fold difference (95% CI 1.19 to 5.30) amounting to 1.33 doubling doses of AMP. There was no change in lymphocyte $\beta_2$ adrenoceptor parameters or in airway $\beta_2$ adrenoceptor responses to salbutamol between the two phases.

Conclusions – Despite an appropriate rise in female sex hormones during the luteal period, $\beta_2$ adrenoceptor regulation in female asthmatic subjects shows a loss of the normal cyclical pattern. In addition, there were cyclical changes in airway responsiveness to AMP which was highest during the premenstrual period. Thus, drugs such as theophylline which block adenosine receptors warrant investigation in premenstrual asthma.

Keywords: asthma, $\beta_2$ adrenoceptor, women, AMP responsiveness.
menstrual deterioration in asthma control. The median consumption of $\beta_2$ agonist was 0.8 puffs/day and 10 subjects were receiving inhaled corticosteroid in a median dose of 800 $\mu$g beclomethasone daily (range 200–2000 $\mu$g). Two subjects were on oral theophyllines (250 $\text{mg}$ and 600 $\text{mg}$ daily).

**STUDY DESIGN**

Subjects kept a diary record of morning and evening PEF values using a Wright’s peak flow meter (Airmed, London, UK). The best of three successive readings was recorded. Subjects attended the laboratory on two separate days, during the follicular (days 1–6) and luteal (days 21–24) phases of the menstrual cycle, day 1 being the first day of the menses. Before each visit inhaled bronchodilators were withheld for eight hours and long acting $\beta_2$ agonists and oral theophyllines for 24 hours. Inhaled corticosteroids were continued unchanged. Both visits were made at the same time of day at 09.00 hours.

At each visit an intravenous cannula was inserted into an antecubital vein, and after 30 minutes rest blood was removed for measurement of serum levels of oestradiol and progesterone, eosinophil cationic protein (ECP) and lymphocyte $\beta_2$ adrenoceptor parameters. Airway responsiveness to AMP was evaluated using a standard challenge protocol. After bronchial provocation subjects were rested until FEV$_1$, returned to within $\pm$5% of the baseline value. A dose-response curve to inhaled salbutamol via a spacing device (Ventolin metered dose inhaler, Volumatic, Allen & Hanbury’s, Uxbridge, UK) was then constructed by giving cumulative doubling doses of 100 $\mu$g, 200 $\mu$g, 400 $\mu$g, 800 $\mu$g, and 1600 $\mu$g. Measurements of FEV$_1$, FEF$_{25-75}$, plasma potassium levels and postural finger tremor were made at baseline and 20 minutes after each dose increment, with each dose increment given every 30 minutes.

**MEASUREMENTS**

FEV$_1$ and FEF$_{25-75}$ were measured according to American Thoracic Society criteria with a Vitalograph compact spirometer equipped with a pneumotachograph head and pressure transducer, and on-line computer-assisted determination of FEV$_1$ and FEF$_{25-75}$. Forced expiratory manoeuvres were performed from total lung capacity to residual volume. The best FEV$_1$ value was taken from three consistent measurements, and the FEF$_{25-75}$ was taken from the best test of three consistent forced expiratory curves. A coefficient of variation of less than 3% was considered as acceptable.

Bronchial challenge was performed using a Nebicheck nebuliser controller (PK Morgan Ltd) with a System 22 Acorn nebuliser (Medic-Aid Ltd) with a driving pressure of 20 psi (138 kPa). The nebuliser was activated for 1.2 seconds from the initiation of inspiration. Fresh solutions of adenosine 5’-monophosphate (AMP; Sigma, Poole, UK) were made up in normal saline on each study day in a range of concentrations from 0.04 mg/ml to 800 mg/ml. Subjects inhaled five breaths of normal saline control solution followed by sequential doubling concentrations of AMP given at three minute intervals. FEV$_1$ was measured one minute after each administration of saline and AMP. The test was terminated when a 20% fall in FEV$_1$, from the post-saline value was attained. A log-dose response curve was constructed and PC$_{20}$ was calculated by linear interpolation.

Plasma levels of potassium (K) were measured by flame photometry (IL943 Analyser, Instrumentation Laboratory Ltd, Warrington, UK) with analysis done at the end of the study and samples assayed in duplicate. The intra-assay and interassay coefficients of variation for analytical imprecision were 0.93% and 0.79%, respectively.

Postural finger tremor was measured by a previously validated method using an accelerometer transducer (Entran Ltd, Ealing, UK). Four recordings were made and the results stored on a computer for subsequent spectral analysis of total tremor power of more than 2 Hz (mg$^2$/s) with computer assisted autocovariance. The mean of three consistent recordings was subsequently analysed.

Lymphocyte $\beta_2$ adrenoceptor parameters included receptor density (Bmax), binding affinity (Kd), and maximal cAMP response to isoprenaline (Emax), measured as previously described. In brief, 40 ml whole blood was collected into tubes containing ethylenediamine tetraacetic acid diluted to 50 ml with phosphate buffered saline (PBS) and then two equal portions were centrifuged with 15 ml Lymphoprep (Nycomed Pharma AS, Oslo, Norway). The lymphocyte layer was removed and, after two further washes with PBS and centrifugation, the lymphocyte pellet was removed and resuspended in 5 ml PBS. Lymphocyte Bmax and Kd were determined with $^{125}$I-iodocyanopindolol (ICYP, NEN-DuPont (UK) Ltd, Stevenage, UK) at eight concentrations between 5 and 160 pmol/l. CGP 12177 (Ciba-Geigy, Basle, Switzerland) was added to half the tubes to prevent ICYP binding to receptor sites, thus allowing non-specific binding to be evaluated. Counts were determined with a gamma camera (LKB Wallac, Wallac OY Pharmacia, Turku, Finland) and specific binding was calculated from total binding minus non-specific binding. The interassay coefficients of variation for analytical imprecision were 10.3% for Bmax and 5.9% for Kd. A radioimmunoassay technique (Incstar, Stillwater, USA) was used to evaluate cyclic AMP levels (Emax) following suspension in PBS containing theophylline (100 $\mu$m) and bovine serum albumin and stimulation with isoprenaline 10$^{-4}$ M. The intra-assay and interassay coefficients of variation for analytical imprecision were 2.7% and 10.2%, respectively.

Serum levels of oestradiol (Sorin Biomedica, Saluggia, Italy), progesterone (Incstar, Stillwater, USA) and ECP (Pharmacia AB, Uppsala, Sweden) were measured by radioimmunoassay. The intra-assay coefficients of variation for analytical imprecision were 2.9%, 6.3% and 6.3%, respectively.
Table 1  Mean (95% CI) values for sex hormones, AMP airway reactivity, lymphocyte β2 adrenoceptor parameters, eosinophil cationic protein (ECP), peak responses for salbutamol dose-response curve, and peak flow readings during the follicular and luteal phases of the menstrual cycle (n = 15)

<table>
<thead>
<tr>
<th></th>
<th>Follicular</th>
<th>Luteal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oestradiol (pmol/l)</td>
<td>1.9 (0.9 to 2.9)</td>
<td>1.7 (0.9 to 2.7)</td>
</tr>
<tr>
<td>Progesterone (nmol/l)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bmax (fmol/10⁶ cells)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kd (pmol/l)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Emax (fmol/10⁶ cells)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ECP (μg/l)</td>
<td>4.4 (2.8 to 6.0)</td>
<td>4.78 (3.2 to 6.34)</td>
</tr>
<tr>
<td>Peak delta FEV1 (l)</td>
<td>0.48 (0.4 to 0.55)</td>
<td>0.43 (0.36 to 0.51)</td>
</tr>
<tr>
<td>Peak delta FEF25–75 (l/s)</td>
<td>1.31 (1.12 to 1.51)</td>
<td>1.10 (0.91 to 1.30)</td>
</tr>
<tr>
<td>Peak delta K (mmol/l)</td>
<td>−0.62 (−0.76 to −0.47)</td>
<td>−0.56 (−0.71 to −0.41)</td>
</tr>
<tr>
<td>Morning PEFR (l/min)</td>
<td>402 (388 to 416)</td>
<td>409 (395 to 423)</td>
</tr>
<tr>
<td>Evening PEFR (l/min)</td>
<td>424 (410 to 437)</td>
<td>426 (412 to 439)</td>
</tr>
<tr>
<td>Diurnal variability (l/min)</td>
<td>21 (15 to 27)</td>
<td>18 (12 to 24)</td>
</tr>
</tbody>
</table>

Bmax = receptor density; Kd = binding affinity; Emax = maximal cAMP response to isoprenaline; ECP = eosinophil cationic protein; FEV = forced expiratory volume in one second; FEF = forced expiratory flow; PEFR = peak expiratory flow rate.

Results

The subjects in our study showed a 2.5-fold increase in airway responsiveness to AMP in the luteal phase during the premenstrual period. Previous studies have not shown any changes in airway responsiveness during the menstrual cycle. These have used methacholine and histamine, which are agents that act directly on airway smooth muscle. AMP, on the other hand, induces bronchoconstriction indirectly by activating mast cells to release bronchoconstrictor mediators. It may be that increased AMP responsiveness during the luteal period is caused by sensitisation of adenosine receptors on mast cells by sex hormones resulting in a lower threshold for mediator release in response to adenosine. Against this hypothesis is our finding of no correlation between hormone levels and PC20. The influence of female sex hormones is not only confined to airway responsiveness changes but is also evident in skin prick test reactions to histamine and allergen with greater weal and flare reactions during the early luteal phase. Furthermore, it has recently been reported that hormone replacement therapy may increase the risk of developing asthma in postmenopausal women and this may be related to the dose of the oestrogen component and duration of use.

Our study has limitations which we recognise. Firstly, we did not have a control group of non-asthmatic subjects for comparison. The reason for this was that it would not be possible to compare PC20 values in normal versus asthmatic airways because of confounding effects of airway geometry, even when using airways conductance. Secondly, our patients were stable and did not exhibit premenstrual asthma as such. Nonetheless, we felt at the outset that it would be valid to look at such patients as a way of investigating possible mechanisms for sex hormone modulation of airway and receptor function.

Despite an appropriate rise in luteal phase sex hormones in our group of asthmatic subjects, β2 adrenoceptor parameters exhibited a loss of normal cyclical regulation previously described in normal women. It is unlikely that this is due to the effects of exposure to exogenous β2 agonist as their drug consumption was minimal. In this respect, we have recently shown that exogenous progesterone but not oestrogen up-regulates follicular phase lymphocyte β2 adrenoceptor in normal women and this raises the possibility that, in asthmatic patients, there may be subsensitivity to the postovulatory rise in endogenous progesterone. The lack of difference in serum AMP levels probably reflects the low levels observed in this group of stable patients with mild disease.

What is the clinical implication of our findings? In patients with stable asthma it is important to appreciate that the intrinsic variability of bronchial hyperresponsiveness is such that PC20 values can vary by up to twofold – that is, one doubling dose. Our findings in this study are therefore likely to have clinical relevance as it exceeds the limit of biological variability. Hence, this change in airway responsiveness from the follicular to the luteal
phase may possibly explain the worsening symptoms observed during the premenstrual period, although the latter was not experienced by our group of mild asthmatic subjects. It is conceivable that these changes may be more clinically significant in patients with more severe disease. Whether treatment for premenstrual asthma will involve drugs such as theophylline, sodium cromoglycate, or nedocromil sodium which antagonise adenosine receptors requires further research.

This work was supported by the National Asthma Campaign.

5 Benyon HLC, Garbett ND, Barnes PJ. Severe premenstrual exacerbations of asthma. Effect of intramuscular progesterone. Lancet 1988a;i:370–2.
Loss of normal cyclical beta 2 adrenoceptor regulation and increased premenstrual responsiveness to adenosine monophosphate in stable female asthmatic patients.

K S Tan, L C McFarlane and B J Lipworth

Thorax 1997 52: 608-611
doi: 10.1136/thx.52.7.608

Updated information and services can be found at:
http://thorax.bmj.com/content/52/7/608

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
- Asthma (1782)
- Drugs: respiratory system (526)
- Airway biology (1100)
- Lung function (773)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/